)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Poolbeg Pharma
Poolbeg Pharma (POLB) investor relations material
Poolbeg Pharma H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary29 Sep, 2026
Executive summary
Advanced POLB 001 through regulatory, operational, and commercial milestones, including MHRA CTA and positive FDA pre-IND meeting.
Initiated the TOPICAL trial in relapsed/refractory multiple myeloma patients, with eight of ~30 participants dosed and strong recruitment momentum.
Strengthened intellectual property portfolio with new patent grants in multiple jurisdictions.
Expanded Scientific Advisory Board with appointment of a cancer immunotherapy expert.
Financial highlights
Cash balance of £4.8 million as of 30 June 2026, down from £10.0 million at 30 June 2025.
Loss for the period was £1.9 million, improved from £2.2 million in H1 2025.
R&D expenses increased to £0.9 million (H1 2025: £0.5 million); administrative expenses decreased to £1.3 million (H1 2025: £2.0 million).
Successful £3.5 million fundraising in July 2026, extending cash runway into Q2 2028.
Outlook and guidance
Both POLB 001 TOPICAL and oral GLP-1 proof-of-concept trials are fully funded through completion.
Oral GLP-1 proof-of-concept study expected to commence in H2 2026.
Focus remains on continued recruitment for the TOPICAL trial and advancing partnering discussions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Poolbeg Pharma
- Interim safety data support continued POLB 001 development for CRS prevention and commercial momentum.POLB
Study update - POLB 001 targets CRS prevention in cancer immunotherapy, aiming for a >$10B market.POLBCompany presentation
- POLB 001 targets a >$10B market as a first-in-class CRS preventative, with key trials underway.POLBCorporate presentation
- POLB 001 nears pivotal CRS data as oral GLP-1 and pipeline progress, backed by strong funding.POLBH2 2025
- Phase IIa trial of POLB 001 targets CRS prevention in myeloma and a $10B+ market.POLBStudy Update
- Cash runway to 2027, POLB 001 gains FDA Orphan status, and key trials advance on schedule.POLBH1 2025
- Advancing breakthrough therapies in oncology and obesity with strong funding and near-term catalysts.POLBCompany Presentation
- Advanced pipeline, strong cash, and expanded IP; loss £5.8m, focus on high-value trials.POLBH2 2024
- POLB001 gains FDA orphan status, with phase 2A trial and $10B+ market potential ahead.POLBInvestor Update
Poolbeg Pharma
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage